A Phase III randomized, open-label, international, multicenter study evaluating the efficacy and safety of mosunetuzumab plus lenalidomide in comparison to anti-CD20 monoclonal antibody plus chemotherapy in subjects with previously untreated FLIPI 2-5 follicular lymphoma

National acute promyelocytic leukemia (APL) observational study NAPOLEON‐Register der Deutschen AML Intergroup

Prospective multicenter registry for neonates, infants, children, adolescents, and adults with neuroblastic tumours.

Dieses Single Patient Request (SPR) / Named Patient Program (NPP) / Intermediate Expanded Access Program (I-EAP) soll einen frühzeitigen Zugang zu Niraparib/Abirateronacetat-Kombination (JNJ- 67652000) zur Anwendung mit Prednison oder Prednisolon vor der Zulassung ermöglichen, um einen kritischen ungedeckten Bedarf bei Patienten mit Prostatakrebs zu decken, die ein metastasiertes kastrationsresistentes Prostatakarzinom (mCRPC) entwickelt haben und bei denen homologe Rekombinationsreparatur (HRR)-Genveränderungen (Keimbahn und/oder somatisch) positiv sind.

Prävention von frühen Darmkrebserkrankungen - PEARL

A randomized phase II study to evaluate the safety and efficacy of trastuzumab deruxtecan versus CDK4/6 inhibitor based endocrine therapy as first line therapy of HR-positive and HER2-low/ultralow advanced breast cancer patients classified as non-luminal subtype according to gene expression profiling

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Treatment-Naive Metastatic Pancreatic Ductal Adenocarcinoma

PRODIGE 107- ENGIC 01- COLOSOTO

A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma